DE69233736D1 - Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit - Google Patents
Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-KrankheitInfo
- Publication number
- DE69233736D1 DE69233736D1 DE69233736T DE69233736T DE69233736D1 DE 69233736 D1 DE69233736 D1 DE 69233736D1 DE 69233736 T DE69233736 T DE 69233736T DE 69233736 T DE69233736 T DE 69233736T DE 69233736 D1 DE69233736 D1 DE 69233736D1
- Authority
- DE
- Germany
- Prior art keywords
- tau protein
- epitopes
- alzheimer
- diagnosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000013498 tau Proteins Human genes 0.000 title abstract 5
- 108010026424 tau Proteins Proteins 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 230000026731 phosphorylation Effects 0.000 title abstract 2
- 238000006366 phosphorylation reaction Methods 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91120974A EP0544942A1 (de) | 1991-12-06 | 1991-12-06 | Neue Werkzeuge für die Diagnose und die Behandlung der Alzheimer-Krankheit |
EP92119551 | 1992-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69233736D1 true DE69233736D1 (de) | 2008-07-24 |
Family
ID=26129111
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69233767T Expired - Lifetime DE69233767D1 (de) | 1991-12-06 | 1992-12-07 | Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit |
DE69233736T Expired - Lifetime DE69233736D1 (de) | 1991-12-06 | 1992-12-07 | Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit |
DE69230148T Expired - Fee Related DE69230148T2 (de) | 1991-12-06 | 1992-12-07 | Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit. |
DE69233723T Expired - Lifetime DE69233723T2 (de) | 1991-12-06 | 1992-12-07 | Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69233767T Expired - Lifetime DE69233767D1 (de) | 1991-12-06 | 1992-12-07 | Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69230148T Expired - Fee Related DE69230148T2 (de) | 1991-12-06 | 1992-12-07 | Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit. |
DE69233723T Expired - Lifetime DE69233723T2 (de) | 1991-12-06 | 1992-12-07 | Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit |
Country Status (10)
Country | Link |
---|---|
US (2) | US6200768B1 (de) |
EP (5) | EP0911398B1 (de) |
JP (4) | JPH07507044A (de) |
AT (4) | ATE438716T1 (de) |
AU (2) | AU681071B2 (de) |
CA (1) | CA2125298A1 (de) |
DE (4) | DE69233767D1 (de) |
DK (1) | DK0618968T3 (de) |
ES (2) | ES2302343T3 (de) |
WO (1) | WO1993011231A1 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010913A (en) * | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
JPH06239899A (ja) * | 1993-02-12 | 1994-08-30 | Teijin Ltd | ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法 |
GB2295395B (en) * | 1993-08-12 | 1998-04-01 | Inst Of Psychiatry | Models of Alzheimer's disease |
GB9316727D0 (en) * | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
EP0737208B1 (de) * | 1993-12-21 | 2006-08-02 | Innogenetics N.V. | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
AU710952B2 (en) * | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
GB9610829D0 (en) * | 1996-05-23 | 1996-07-31 | Medical Res Council | Screening of agents for treatment of azlheimers disease |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
AU744881B2 (en) * | 1997-09-04 | 2002-03-07 | Board Of Trustees Of The Leland Stanford Junior University | Assays for detecting modulators of cytoskeletal function |
US6797478B1 (en) * | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
US20020002270A1 (en) | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
US7640062B2 (en) | 2000-05-08 | 2009-12-29 | Brainsgate Ltd. | Methods and systems for management of alzheimer's disease |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
EP1925315A3 (de) * | 2001-02-27 | 2009-11-18 | Blanchette Rockefeller Neurosciences Institute | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung |
CN1549721B (zh) | 2001-02-27 | 2012-03-07 | 布朗歇特洛克菲勒神经科学研究所 | 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病 |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
TWI265164B (en) | 2001-09-21 | 2006-11-01 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
PL368816A1 (en) | 2001-09-21 | 2005-04-04 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
CA2477604A1 (en) * | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
CA2483635A1 (en) * | 2002-04-25 | 2003-11-06 | Alon Shalev | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
JP2006515999A (ja) * | 2002-11-14 | 2006-06-15 | ブレインズゲート リミティド | 刺激のための外科用ツール及び技法 |
ZA200505258B (en) | 2002-12-16 | 2006-09-27 | Mitsubishi Pharma Corp | 3-Substituted-4-pyrimidone derivatives |
WO2004056080A1 (en) * | 2002-12-18 | 2004-07-01 | Novartis Ag | Endothelial cell specifically binding peptides |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
GB2398533B (en) * | 2003-02-19 | 2005-11-16 | Gillette Co | Safety razors |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
WO2005058374A1 (en) * | 2003-12-15 | 2005-06-30 | Tongji Medical Center | Methods and compositions for modulating tau in vivo |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
US8221804B2 (en) * | 2005-02-03 | 2012-07-17 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US20070134724A1 (en) * | 2005-08-04 | 2007-06-14 | Peter Davies | Phosphorylation of tau by abl |
US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
DK2004155T3 (en) | 2006-03-29 | 2018-04-30 | Wista Lab Ltd | PROTEIN AGGREGATION INHIBITORS |
ATE478058T3 (de) | 2006-03-29 | 2010-09-15 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008089961A1 (en) * | 2007-01-22 | 2008-07-31 | University Of Zurich | Use of phosphatase inhibitors for the treatment of neurodegenerative diseases |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
EP2669386A1 (de) | 2008-07-28 | 2013-12-04 | Blanchette Rockefeller Neurosciences Institute | Stimulierte ausgelöste genomische Profilmarker von Morbus Alzheimer |
EP3586839A1 (de) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen |
US9464122B2 (en) * | 2008-08-20 | 2016-10-11 | Oligomerix, Inc. | Methods and compositions comprising tau oligomers |
WO2010021755A2 (en) * | 2008-08-20 | 2010-02-25 | Oligomerix, Inc. | Tau protease compositions and methods |
FR2940972B1 (fr) * | 2009-01-09 | 2015-07-31 | Isp Investments Inc | Nouveaux peptides anti-age et composition cosmetique et/ou pharmaceutique les contenant |
CA3120504A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
SG177637A1 (en) * | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
JP6124591B2 (ja) * | 2009-08-28 | 2017-05-10 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | タウオリゴマーに結合する抗体 |
US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
EP2480891B1 (de) | 2009-09-24 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fkbp52-tau-interaktion als neuartiges therapeutisches target zur behandlung von neurologischen erkrankungen im zusammenhang mit tau-störungen |
US20110144029A1 (en) * | 2009-09-30 | 2011-06-16 | Board Of Regents, The University Of Texas System | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases |
WO2011041761A1 (en) | 2009-10-02 | 2011-04-07 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of alzheimer's disease |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP3533803B1 (de) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antikörper |
TW201216985A (en) | 2010-10-07 | 2012-05-01 | Ac Immune Sa | Pharmaceutical composition |
CA2817973C (en) | 2010-10-15 | 2019-06-25 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
CN105853439A (zh) | 2011-02-11 | 2016-08-17 | 维斯塔实验室有限公司 | 吩噻嗪二胺鎓盐和其用途 |
EP2702073B1 (de) | 2011-04-28 | 2017-02-08 | Universität Leipzig | Polymutante tau-proteinvarianten und ihre verwendung zur rekapitulierung von menschlichen tauopathien |
US9506051B2 (en) | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
SG10201912964PA (en) * | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
EP2764022B9 (de) | 2011-10-07 | 2017-02-22 | AC Immune S.A. | Phosphospezifischer antikörper zur tau-erkennung |
CA2856235A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla for the treatment of neurodegenerative disorders |
CN104781278B (zh) | 2012-07-03 | 2018-06-12 | 华盛顿大学 | 针对tau的抗体 |
WO2014141124A1 (en) * | 2013-03-13 | 2014-09-18 | Institut National De La Sante Et De La Recherche Medicale | Erk-pathway activating compound for preventing or treating leptin resistance |
MX2015012872A (es) | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anticuerpos anti-tau y metodos de uso. |
EP2878335B1 (de) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implantat und implantationssystem für nervenstimulator |
PL3083680T3 (pl) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania |
WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
WO2016112078A2 (en) * | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
EP3313877B1 (de) | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Humanisierte anti-tau(ps422)-antikörper und verfahren zur verwendung |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
US10265497B2 (en) | 2015-11-24 | 2019-04-23 | Massachusetts Institute Of Technology | Systems and methods for treating dementia |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
MY197836A (en) | 2016-07-12 | 2023-07-20 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
CN110267985B (zh) | 2017-01-04 | 2023-05-23 | H.隆德贝克有限公司 | 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体 |
US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
KR20230015501A (ko) * | 2017-10-10 | 2023-01-31 | 메사추세츠 인스티튜트 오브 테크놀로지 | 뇌에서 감마 진동을 동기화하기 위해 시각 자극을 이용한 치매 치료 |
US11241586B2 (en) | 2017-10-10 | 2022-02-08 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874694A (en) * | 1987-04-07 | 1989-10-17 | The Rockefeller University | Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders |
DE3726721A1 (de) * | 1987-08-11 | 1989-02-23 | Koehler Chemie Dr Franz | Verwendung eines calcium-chelats der ethanolaminophosphorsaeure zur prophylaxe oder therapie |
GB8724412D0 (en) * | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
IE911869A1 (en) * | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
DE4028970A1 (de) | 1990-09-12 | 1992-03-19 | Kettner Verpackungsmaschf | Transportrolle |
DE69232121T2 (de) | 1991-08-09 | 2002-06-20 | Massachusetts Inst Technology | Verwendungen einer proteinkinase von ton und neurofilament pk40 |
CA2203910A1 (en) * | 1994-10-28 | 1996-05-09 | Eckhard Dr. Mandelkow | Novel protein kinase (npk-110) |
-
1992
- 1992-12-07 AT AT98121176T patent/ATE438716T1/de not_active IP Right Cessation
- 1992-12-07 JP JP5509840A patent/JPH07507044A/ja active Pending
- 1992-12-07 ES ES98121177T patent/ES2302343T3/es not_active Expired - Lifetime
- 1992-12-07 DE DE69233767T patent/DE69233767D1/de not_active Expired - Lifetime
- 1992-12-07 EP EP98121175A patent/EP0911398B1/de not_active Expired - Lifetime
- 1992-12-07 EP EP93901671A patent/EP0618968B1/de not_active Revoked
- 1992-12-07 EP EP98121177A patent/EP0909814B1/de not_active Expired - Lifetime
- 1992-12-07 AT AT98121175T patent/ATE398176T1/de not_active IP Right Cessation
- 1992-12-07 DE DE69233736T patent/DE69233736D1/de not_active Expired - Lifetime
- 1992-12-07 EP EP98121176A patent/EP0911390B1/de not_active Expired - Lifetime
- 1992-12-07 DE DE69230148T patent/DE69230148T2/de not_active Expired - Fee Related
- 1992-12-07 AT AT93901671T patent/ATE185599T1/de not_active IP Right Cessation
- 1992-12-07 DE DE69233723T patent/DE69233723T2/de not_active Expired - Lifetime
- 1992-12-07 US US08/244,603 patent/US6200768B1/en not_active Expired - Lifetime
- 1992-12-07 AT AT98121177T patent/ATE386115T1/de not_active IP Right Cessation
- 1992-12-07 EP EP08010527A patent/EP2009104A1/de not_active Withdrawn
- 1992-12-07 DK DK93901671T patent/DK0618968T3/da active
- 1992-12-07 ES ES93901671T patent/ES2136654T3/es not_active Expired - Lifetime
- 1992-12-07 CA CA002125298A patent/CA2125298A1/en not_active Abandoned
- 1992-12-07 AU AU32560/93A patent/AU681071B2/en not_active Ceased
- 1992-12-07 WO PCT/EP1992/002829 patent/WO1993011231A1/en not_active Application Discontinuation
-
1997
- 1997-07-10 AU AU28656/97A patent/AU707736B2/en not_active Ceased
-
1999
- 1999-05-19 JP JP11139314A patent/JP2000032983A/ja active Pending
- 1999-05-19 JP JP11139268A patent/JP2000026498A/ja active Pending
- 1999-05-19 JP JP11139294A patent/JP2000037188A/ja active Pending
-
2008
- 2008-08-04 US US12/185,319 patent/US20090162336A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69233736D1 (de) | Phosphorylierungsepitope aus dem Tau-Protein zur Diagnose und Behandlung der Alzheimer-Krankheit | |
DE69129302T2 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
DE69334246D1 (de) | Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome | |
DE59705683D1 (de) | IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG | |
DE69432629D1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
NO20002380D0 (no) | Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering | |
JPS63222693A (ja) | Apcポリペプチドの前駆体蛋白質、この遺伝情報を指定するdna、およびdnaおよび前記蛋白質の診断的使用 | |
NO941371D0 (no) | T-celle-epitoper av hovedallergener av Dermatophagoides (hus-stöv-midd) | |
ATE182180T1 (de) | Lamanin-ketten: diagnostische und therapeutische verwendung | |
DE3854767T2 (de) | Diagnostika und Impfstoffe für Mycobacteria in der Volksgesundheit, in der medizinischen und veterinären Praxis | |
WO2002012284A3 (en) | Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease | |
ATE230416T1 (de) | Neue mittel zur diagnose von gefässerkrankungen | |
DE69517521D1 (de) | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes | |
DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
ATE170754T1 (de) | Eine caseinfraktion zur therapeutischen vorbeugenden und/oder diagnostischen verwendung bei atemweginfektionen | |
ATE462717T1 (de) | Verfahren und zusammensetzungen für die diagnose und die behandlung von krankheiten, die mit eisenüberschuss oder eisenmangel assoziiert sind | |
ATE321135T1 (de) | Verfahren zur diagnose und behandlung neurologischer erkrankungen | |
FI901371A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten halogeeni-3,4-dihydro-bentsotiopyranyyliamiinien valmistamiseksi | |
ATE240352T1 (de) | Komplexverbindungen zur diagnose von gefässerkrankungen | |
ATE334145T1 (de) | Neues menschliches ulip/crmp protein und seine verwendung zur diagnose zur behandlung von krebs und von neurologischen paraneoplastischen syndromen | |
Biedler et al. | Postoperative cognitive dysfunction in elderly patients. Based on the publication of the ISPOCD 1 study group in Lancet (1998) 351: 857-861 | |
ATE193707T1 (de) | Synthetische peptide, die sequenzen aus faktor viia enthalten und deren verwendung | |
Shanks et al. | Evidence of discrete brain dysfunction underlying delusions of different content in Alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
R071 | Expiry of right |
Ref document number: 911398 Country of ref document: EP |